ID   HEC-1
AC   CVCL_1274
SY   HEC1; Human Endometrial Cancer-1; HEC-B-296
DR   CLO; CLO_0037162
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 867
DR   BioSample; SAMN03472810
DR   cancercelllines; CVCL_1274
DR   Cell_Model_Passport; SIDM00596
DR   ChEMBL-Cells; CHEMBL3308740
DR   ChEMBL-Targets; CHEMBL1075462
DR   Cosmic; 907051
DR   Cosmic-CLP; 907051
DR   DepMap; ACH-001517
DR   EGA; EGAS00001000978
DR   GDSC; 907051
DR   GEO; GSM827285
DR   GEO; GSM1669873
DR   IARC_TP53; 21367
DR   JCRB; JCRB0042
DR   LINCS_HMS; 50014
DR   LINCS_LDP; LCL-1496
DR   PharmacoDB; HEC1_523_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1274
DR   PubChem_Cell_line; CVCL_1274
DR   Wikidata; Q54882245
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   PubMed=2064198;
RX   PubMed=4673779;
RX   PubMed=4678779;
RX   PubMed=7448794;
RX   PubMed=9290701;
RX   PubMed=12227503;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; ClinVar=VCV001736936; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=89.14%; East Asian, South=10.41%; South Asian=0.45%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): Cosmic-CLP; DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11 (JCRB)
ST   D13S317: 11,16 (Cosmic-CLP; DepMap)
ST   D16S539: 11,12
ST   D18S51: 16,20,21
ST   D21S11: 30,31
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 11
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   Penta D: 9,13
ST   Penta E: 11
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003).
//
RX   PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x;
RA   Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y.,
RA   Ohno E., Iida T.;
RT   "Establishment and characterization of human endometrial cancer cell
RT   lines.";
RL   Ann. N. Y. Acad. Sci. 622:402-421(1991).
//
RX   PubMed=4673779; DOI=10.1016/0002-9378(72)90861-7;
RA   Kuramoto H., Tamura S., Notake Y.;
RT   "Establishment of a cell line of human endometrial adenocarcinoma in
RT   vitro.";
RL   Am. J. Obstet. Gynecol. 114:1012-1019(1972).
//
RX   PubMed=4678779;
RA   Kuramoto H.;
RT   "Studies of the growth and cytogenetic properties of human endometrial
RT   adenocarcinoma in culture and its development into an established
RT   line.";
RL   Acta Obstet. Gynaecol. Jpn. 19:47-58(1972).
//
RX   PubMed=7448794;
RA   Gal D., MacDonald P.C., Porter J.C., Smith J.W., Simpson E.R.;
RT   "Effect of cell density and confluency on cholesterol metabolism in
RT   cancer cells in monolayer culture.";
RL   Cancer Res. 41:473-477(1981).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x;
RA   Kuramoto H., Hamano M., Imai M.;
RT   "HEC-1 cells.";
RL   Hum. Cell 15:81-95(2002).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//